English (UK)
中文版Jianmin Pharma Group 
Jianmin Group (600976.SSE) is an integrated pharmaceutical company with a major focus on pediatric product development, manufacture, and marketing. Founded in 1953, headquartered in Wuhan, the largest city in Central China, its history can be traced back to 17th century. Jianmin has been a famous pharma brand in China among children and their parents for generations. Its rich pediatric portfolio ranges from nutrition, hematology, respiratory, digestive, CNS, to infections and common cold as well.
Mr Wei Li
Head of Business DevelopmentJIAYUHONGDE INVESTMENT （SHANGHAI）Ltd
Investment management company commits to authentic relationships, communications, and promises，builds productive operations and profitable businesses，invests in the field of medical technology, new energy source etc.
梦龄 徐
高级投资经理Kaitai Capital
Kaitai is a biotech venture fund with about 40 biotech portfolio companies. Kaitai's fund size is about 7 billions dollars. They are positively looking for cutting edge technologies.
Eric Chang
Executive DirectorQi Jin
董事总裁kangyuan biomedical tech
medical device company focUnited States on blood purification
chunchao jia
department leaderKawin
Kawin Technology is a Chinese biopharma engaging in liver disease and virus-related disease.
The turnover in 2019 is over 800 million RMB (115 millon USD).
We are now in IPO process and projected to be listed in China this year.
The turnover in 2019 is over 800 million RMB (115 millon USD).
We are now in IPO process and projected to be listed in China this year.
Mr. Yu Cai
BD HEADKintor Pharma
Founded in 2009, Kintor Pharmaceuticals concentrates on the R&D and industrialization of “best-in-class” and “first-in-class” innovative drugs and strives to become a leading enterprise in the R&D and commercialization of innovative therapies. On 22 May 2020, Kintor Pharmaceuticals was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK.
Responsive Web Design powered by 